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Abstract
For better management of patients with febrile neutropenia, our study investigated the epi-
demiologic, microbiologic, and clinical characteristics of adult inpatients with febrile neutro-
penia and their mortality-associated factors. To this end, we carried out a prospective,
observational, multicenter study in 28 Argentinian hospitals between 2007 and 2012. We
included 515 episodes of febrile neutropenia from 346 patients, median age 49 years. Neu-
tropenia followed chemotherapy in 77% of cases, half of the cases due to hematological
malignancies. Most episodes were classified as high-risk according to MASCC criteria, and
53.6% of patients were already hospitalized at the onset of febrile neutropenia. Bloodstream
infections were detected in 14% episodes; whereas an infectious source of fever was identi-
fied in 80% of cases. Mortality rate achieved to 14.95%. The binary regression analysis
showed that persistence of fever at day 7, or neutropenia at day 14, dehydration and tachy-
cardia at the onset of febrile neutropenia as well as prior infections were significantly associ-
ated with mortality. In addition to expanding our current knowledge on the features of adult
patients with febrile neutropenia, present findings provide useful information for better man-
agement of them in Argentina, given the appropriate representativeness of centers partici-
pating in the study.
Introduction
Febrile neutropenia constitutes a differentiated clinical entity that is becoming increasingly
frequent in daily hospital practice. The leading cause of neutropenia results from chemother-
apy in patients with malignancies, making them more susceptible to bacterial infections
because of the reduction of this critical component from innate defense mechanisms [1, 2]. In
turn, chemotherapy damages the integrity of the gastrointestinal mucosa, favoring the invasion
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of endogenous germs [1, 3–6]. Since the ability to develop an adequate inflammatory response
is impaired, the spectrum of clinical manifestations allowing to suspect an infectious process is
also compromised, with fever being frequently the sole indicator of that [1, 5, 7, 8]. The pro-
gression of infection in neutropenic patients may be fast, for which the early administration of
empirical treatment is crucial, even before confirming any infectious source [1, 5, 8].
Current advances in terms of disease physiopathology, new imaging-based diagnosis, as
well as microbiological and serological tests, resulted in better control measures and decreased
morbimortality [5]. Nevertheless, case numbers continue to be significant, making the issue
still relevant in terms of a health problem [1, 9, 10]. On the other hand, changes in the profile
of the etiological agents together with the growing antimicrobial resistance renders the situa-
tion even more complex [5, 6, 8, 10].
It follows that the management of febrile neutropenic patients remains challenging [1, 5,
10]. International and regional guidelines developed for the management of these patients,
also establish the need for a proper epidemiological knowledge from different regional scenar-
ios [5, 6, 8, 10].
Given this background, we sought to identify the epidemiological, microbiological, clinical,
and therapeutic characteristics of patients with febrile neutropenia from centers mostly located
in the central area of Argentina. In a second step, we also searched for factors likely to be asso-
ciated with fatal outcome.
Materials and methods
Participants
All participants provided written and informed consent for the study, which was approved by
the Ethic Committee from the School of Medical Sciencies National University of Rosario on
July 2007 (resolution # 326/2007) in accordance with the World Medical Association’s Decla-
ration of Helsinki.
The study consisted of a multicenter, observational and prospective study of febrile neutro-
penia episodes in adult inpatients from 01-Aug-2007 to 02-Mar-2012, in 28 Hospital Depart-
ments of Internal Medicine from Argentina, led by investigators from “Hospital Provincial del
Centenario” University Hospital. All participating centers habitually treat patients with febrile
neutropenia episodes (FNEs) according to periodically revised local protocols, following
national and international guidelines and recommendations. Inclusion criteria comprised age
�15 years, along with the presence of neutropenia and fever according to the following defini-
tions: for neutropenia a neutrophil count below 500 / mm3; or less than 1,000 / mm3 and likely
to decrease to less than 500 / mm3 in the next 48 hours; in the case of fever, presence of a single
record of axillary temperature > 38.3˚ C, or� 38˚ C for one hour or more.
Day 0 corresponded to the time when the patient fulfilled inclusion criteria and was
included in the study. The existence of an infective source was established provided the clini-
cian made the diagnosis of a clinically documented infection based on clinical and imaging
data. A microbiological infection was confirmed, whenever a microorganism was isolated in
cultured samples from a clinically suspected source.
Criteria for study completion comprised the remission of fever and neutropenia. Informa-
tion on whether the patient remained in the hospital for other reason or had been released
from it was recorded at that time point. Death of the patient or the referral to another care cen-
ter was also regarded as end of study.
For the remission of fever, we considered values lower than 38˚C for the latest 48 hours;
whereas values higher than 500 neutrophils / mm3 for at least during the two preceding days
were regarded as neutrophil recovery.
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Procedures
Evaluation of patients consisted of a complete physical examination, biochemistry and hema-
tology studies, sets of blood cultures, or additional samples from infected sites if needed.
Recorded data included demographic and epidemiologic variables, cause of neutropenia, i.e.,
cancer chemotherapy, underlying disease, and comorbidities. Information on patient anteced-
ents before day 0 included: ambulatory or hospitalized condition at the onset of FNEs, prior
use of antibiotics, presence of previous fungal infection, or neutropenia episodes. Data from
physical examination, routine laboratory tests on admission, blood and urine cultures, use of a
central venous catheter (CVC), empiric antibiotic treatment, administration of granulocyte
colony-stimulating factor (G-CSF), detection of clinical or microbiological infection, evolution
and outcome (death, recovery or referral) were also recorded. The clinical source of fever was
registered by the medical staff according to its location: lung, skin, gastrointestinal tract, uri-
nary, and central nervous system, among others. The biochemistry and microbiological studies
were carried out at each center according to standard procedures.
The MASCC risk index (Multinational Association for Supportive Care in Cancer) [11] was
estimated on admission, as did the ECOG (Eastern Cooperative Oncology Group) perfor-
mance score [12, 13]. The MASCC risk index developed and validated to identify febrile neu-
tropenic patients with different risk of complications and death [8, 14–16], served to separate
individuals into low or high-risk groups (values� or< 21 points, respectively) [11].
The ECOG scale, which is widely used to assess the functional status of cancer patients,
mainly their daily life ability and autonomy, ranged from 0 (patients with autonomy and nor-
mal activity) to 4 (bed-ridden patients at high risk of complications during febrile neutropenia)
[13, 17].
As stated, all patients or their legal representatives provided written informed consent
before enrolment in the study.
Statistical analysis
Quantitative results were expressed as median and 25–75 percentiles when required. Univari-
ate analysis was performed by using the Chi-square test or Fisher’s exact test for categorical
variables, whereas the Mann-Whitney test was employed for continuous variables (survivors
versus non-survivors comparisons). Variables yielding significant differences in univariate
analysis were entered into a binary logistic regression model for the multivariate approach.
The level of statistical significance was set at p<0.05. Data were analyzed by employing the
SPSS package.
Results
Baseline characteristics of the sample population
A total of 346 patients, experiencing 515 FNEs were enrolled. Age at the FNE episode was 49
(34–60) years, distributed among 227 women and 288 men. Nearly half of episodes (46%)
occurred in the range age of 40 to 64 years. Data about patient characteristics on study admis-
sion (day 0) are depicted in Table 1. As shown, 53.6% of patients were already hospitalized at
the onset of the episode, whereas one-third of them had the antecedent of prior FNEs or were
undergoing antibiotic treatment before developing neutropenia. Among those receiving pro-
phylaxis (n = 63, 12.2%), regimens included cotrimoxazole (n = 37, 7.2%), quinolones (n = 19,
3.7)%, or other compounds (n = 7, 1.3%).
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The main comorbidities were HIV infection, treatment with immunosuppressants or corti-
costeroids, and diabetes. The MASCC risk index corresponded to the high-risk group (<21) in
95.3% of cases, while 47.4% of patients presented a�2 ECOG score.
Table 1. Characteristics of patients at the beginning of 515 of febrile neutropenia episodes.
Sex Men 288 (55.9%)
Women 227 (44.1%)
Age (years) 49 (34–60)
Comorbidities HIV 51 (9.9%)
Immunosuppressants 49 (9.5%)






Other antecedents Radiotherapy 39 (7.6%)
Bone marrow transplantation 18 (3.5%)
Previous episodes of neutropenia 167 (32.4%)
Central venous catheter at the onset of
FNE
98 (19%)
Previous fungal invasive infection 27 (5.2%)
Hospitalized at the onset of FNE 276 (53.6%)
Prior use of antimicrobials 161 (31,3%)
Bacterial prophylaxis 63 (12.2%)
Prior infection at the onset of FNE 98 (19%)
No antibiotics 354 (68.7%)





ECOG score (n = 472)1 ECOG 0 89 (18.9%)
ECOG 1 159 (33.7%)
ECOG 2 95 (20.1%)
ECOG 3 93 (19.7%)
ECOG 4 36 (7.6%)
MASCC risk index at the onset of FNE High risk <21 491 (95.3%)
Low risk�21 24 (4.7%)
Laboratory at the onset of FNE Leukocytes (cells/mm3) 800 (400–1400)
Neutrophils (cells/mm3) 100 (0–348)
Deep Neutropenia (<100 cells/mm3) 242 cases (47%)
Hemoglobin (g/dl) 8,9 (7,4–10.4)
Platelets (cells/mm3) 60000 (18500–120000)
Quantitative values are represented as median (25–75 percentiles). Percentages are indicated in parentheses COP:
chronic obstructive pulmonary disease; CHF: congestive heart failure; CRI: chronic renal insufficiency. ECOG:
Eastern Cooperative Oncology Group; FNE: febrile neutropenia episode; MASCC: Multinational Association for
Supportive Care in Cancer.
1The ECOG score was calculated in 472 episodes.
https://doi.org/10.1371/journal.pone.0224299.t001
Febrile neutropenia in Argentina
PLOS ONE | https://doi.org/10.1371/journal.pone.0224299 October 31, 2019 4 / 15
The median neutrophil counts by total episodes was 100 (0–348) cells/mm3, with 242 FNEs
(47%) showing profound neutropenia (�100 neutrophils / mm3). Tachycardia and tachypnea,
followed by hypotension, dehydration, and oliguria were the most frequent alterations seen on
physical examination at the onset of FNEs (Table 1).
Most FNEs (395) were secondary to chemotherapy, 291 of them due to oncohematological
malignancies, i.e., non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), acute
lymphocytic leukemia (ALL), and Hodgkin lymphoma. Another 104 episodes (20.2%) result-
ing from chemotherapy, had a diagnosis of solid tumors, such as breast, lung, and colorectal
cancer, in decreasing order. In 120 episodes (23.3%), neutropenia was unrelated to chemother-
apy, and due to the presence of primary hematological disorders, infections, drugs or autoim-
mune diseases. In 14 cases, neutropenia causes remained unidentified (Table 2).
Table 2. Causes of neutropenia in the present series of febrile neutropenia episodes.
Cause N
POSTCHEMOTHERAPY–ONCOHEMATOLOGIC MALIGNANCIES (n:291; 56.5%)
Non-Hodgkin Lymphoma 107 (36.8%)
Acute Myeloid leukemia 94 (32.3%)
Acute lymphoblastic Leukemia 43 (14.8%)
Hodgkin disease 17 (5.8%)
Chronic lymphocytic Leukemia 15 (5.2%)
Multiple Myeloma 7 (2.4%)
Others 8 (2.7%)










NEUTROPENIA UNRELATED TO CHEMOTHERAPY (n:106; 20.6%)
Hematological 54 (50.9%)
• Acute Myeloid leukemia 22
• Myelodysplastic syndrome 10
• Aplastic anemia (pancytopenia) 9
• Lymphoproliferative disorders 4
• Tricholeukemia 4
• Acute lymphoblastic Leukemia 3








• Other drugs 5
(Continued)
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Blood cultures performed on day 0 were positive in 72 of FNEs (14%), showing a slight pre-
dominance of Gram-negative bacilli (52.8%). The main isolated microorganism was Escheri-
chia coli, followed by methicillin-sensitive Staphylococcus aureus, Klebsiella pneumoniae, and
pseudomonas species (Table 3).
When analyzing the association between antimicrobial prophylaxis and the type of bacteria
recovered from blood cultures, we found an insignificant trend for Gram-positive predomi-
nance among patients undergoing prophylaxis (5/8 Gram-positive bacteremias from patients
under prophylaxis, versus 29/64 from those with no prophylaxis, p = 0.463). The same trend
was recorded when analyzing prophylaxis according to cotrimoxazole and quinolones treat-
ments (data not shown).
Throughout the evolution of FNEs, one to three additional blood cultures were taken in
312 cases, 33 of them yielding positive results (10.6%). Again, there was a small predominance
of Gram-negative bacilli, with K. pneumoniae being the most frequently isolated one (Table 3).
Urine cultures performed in all FNEs yielded positive results in 49 cases (9.5%); as did another
13 cases during their evolution. In both occasions, E. coli predominated (Table 3).
Mycological blood cultures performed at day 0 (n = 153) were all negatives, whereas in
another 90 samples collected during evolution, the presence of Candida albicans was found in
2 out of them (2.2%).
Stoll cultures were carried out as required. Among 103 stoll cultures performed at the onset
of FNE, 3 of them led to pathogen isolation, which may be incriminated as being possibly
involved in diahrrea (Table 3).
Confirmed infection
In overall, an infectious cause was identified in 80% of FNEs. More than 68% of FNEs
(n = 355) had a diagnosis of an infectious process, based on clinical data (n = 235, 46%) or clin-
ical and microbiological evidence (n = 120, 23%). There were another 58 cases (11%) with a
positive microbiological result but no clinical focus. In the remaining 102 episodes, clinical or
microbiological evidence of infection was lacking.
The distribution of clinical infections at day 0 was as follows: pneumonia (n = 96, 18.6%),
gastrointestinal tract -mostly diarrhea- (n = 84, 16.3%), skin and soft tissues (n = 53, 10.3%),
pharynx/oral cavity (n = 49, 9.5%), severe mucositis-related infections (n = 24, 4.6%), perianal
zone (n = 20, 3.9%), phlebitis (n = 19, 3.7%), CVC-associated infection (n = 9, 1.7%), and
other tissues (n = 8, 1.5%). Some patients presented more than one clinical infection,exhibiting
a similar trend of site distribution, that is pneumonia as the predominant infection throughout
the episode course (n = 31, 6%), followed by affectation of the gastrointestinal tract (n = 20,
3.9%), skin and soft tissues (n = 18, 3.5%), pharynx/oral cavity (n = 14, 2.7%) phlebitis (n = 6,






• Autoimmune diseases 4
• Bone marrow metastasis 2
• Primary humoral immunodeficiency 1
NEUTROPENIA UNRELATED TO CHEMOTHERAPY, UNKNOWN CAUSES (n = 14; 2.7%)
https://doi.org/10.1371/journal.pone.0224299.t002
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Treatment
Two third of FNEs were given G-CSF (n = 341). Information dealing with empiric antibiotic
therapy on day 0 is provided in Table 4. The prevailing antibiotic schedule consisted of the
combination of ceftazidime plus amikacin, followed by piperacillin/tazobactam and
Table 3. Results from cultures performed at day 0 and during the evolution of febrile neutropenia episodes.
Blood cultures Isolated microbe (n) n
Blood cultures at the onset
(n = 515)
Gram-negative bacilli 38
Escherichia coli (18); Klebsiella pneumonia (7); Pseudomonas sp (7);
Acinetobacter baumannii (1); Other Gram-negative bacilli (5)
Gram-positive cocci 34
Methicillin-susceptible Staphylococcus aureus (15); Methicillin-resistant
Staphylococcus aureus (5); Coagulase-negative staphylococci (4); Streptococcus
viridans (4); Streptococcus pneumonia (3); Enterococcus sp. (2); Streptococcus
pyogenes (1)
Total 72
Blood cultures during the
evolution (n = 312)
Isolated microbe (n)
Gram-negative bacilli 18
Klebsiella pneumoniae (7), Escherichia coli (4), Acinetobacter baumannii (3),
Pseudomonas sp (2), Stenotrophomonas maltophilia (1), Klebsiella oxytoca (1)
Gram-positive cocci 15
Staphylococcus coagulase negative (4), Methicillin-susceptible Staphylococcus
aureus (5), Streptococcus viridans (2), Enterococcus faecium (2), Enterococcus
faecalis (1), Methicillin-resistant Staphylococcus aureus (1)
Total 33
Urine culture Isolated microbe (n)
Urine cultures at the onset
(n = 515)
Gram-negative bacilli 40
Escherichia coli (31), Klebsiella pneumonia (4), Enterobacter cloacae(2),
Acinetobacter baumannii (1), Proteus mirabilis (1), Pseudomonas sp (1)
Gram-positive cocci 5
Enterococcus faecalis (2), Coagulase-negative staphylococci (1), Streptococcus







evolution (n = 128)
Isolated microbe (n)
Gram-negative bacilli 10




Stoll cultures at the
onset (n = 103)
Gram- negative bacilli (n) 1
Campylobacter sp.(1)
Parasitosis 2
Cryptosporidium neoformans (1), Blastocystis hominis (1)
Total 3
Stoll cultures during evolution
(n = 22)
None
Microorganisms were indicated according to decreasing order of presentation
https://doi.org/10.1371/journal.pone.0224299.t003
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carbapenems. Vancomycin was initially given in 174 cases (33.8%) whereas in another 101
ones (19.6%) this antibiotic was incorporated throughout the episode evolution. Antifungal
therapy was administered on day 0 (n = 65) or during the follow-up of FNEs (n = 116). Sev-
enty-one cases (13.8%) received antiviral therapy on day 0 including acyclovir (n = 45, 8.7%),
antiretroviral drugs (n = 15, 2.9%) or other compounds (n = 11, 2.1%). Acyclovir recipients
were those presenting cutaneous, mucosal or perianal herpes virus-like lesions. Antiviral treat-
ment, at the onset of FNEs, was more prevalent in HIV-coinfected patients (26/51, 51%) if
compared to the uninfected counterpart (45/460, 9,8%; p<0,001). In the ensuing days, 7 cases
received acyclovir and another one antiretroviral treatments.
End of study
Hospital discharge was indicated in 346 FNEs, and in 77 episodes (14.9%), patients died during
hospitalization. Thirteen episodes were referred to another center whereas, in the remaining
78 ones (15.1%), patients continued to be hospitalized for reasons other than febrile neutrope-
nia. Median values for FNEs length, neutropenia duration, and fever persistence were 8 (5–
13), 5 (3–8.25) and 4 (2–7) days, respectively.
Variables associated with mortality at the end of study
The median neutropenia and fever duration, in days, were higher in fatal cases respect those
who survived: 7.5 (3–13.25; 25–75% percentiles) vs. 5 (3–8), p = 0.003; and 6 (3–12.25) vs. 4
(2–6), p = 0.001, respectively.
Median neutrophil counts was 3 (0–280) for fatal cases, and 100 (0–350) for survivors
(p = 0.033). Neutropenia lower than 50 cells/mm3 as a dichotomic variable was associated with
an increased mortality (p = 0.023), this not being the case for those with neutrophils lower
than 100 cells/mm3 (p = 0.35).
On crude analysis, MASCC risk index category was associated with mortality (Table 5).
Other variables associated with mortality were: hospitalization at the onset of FNE, presence of
CVC at presentation, treated infection before the onset FNEs, hypotension/tachycardia/
tachypnea/dehydration at the onset of FNE, initial use of vancomycin, unremitted fever at day
7 or unremitted neutropenia at day 14, as well as initial positive blood cultures, an ECOG
score� 3,or MASCC risk index<15, and neutrophils<50 cells/mm3 on day 0. Female gender,
Table 4. Use of antimicrobials during febrile neutropenia episodes (n = 515).
Initial antibiotic schedule other than vancomycin Ceftazidime + amikacin 171 (33.2%)
Piperacillin / tazobactam 133 (25.8%)
Carbapenems 60 (11.7%)
Cefepime 40 (7.8%)
Other combinations 111 (21.6%)
Use of vancomycin At day 0 174 (33.8%)
During evolution 101 (19.6%)
Total 275 (53.4%)
Use of antifungals At day 0 65 (12.6%)
During evolution 116 (22.5%)
Total 181 (35.1%)
Use of antivirals At day 0 71 (13.8%)
During evolution 8 (1.6%)
Total 79 (15.3%)
https://doi.org/10.1371/journal.pone.0224299.t004
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chemotherapy for a solid tumor cause of FNEs, and initial empirical treatment with ceftazi-
dime plus amikacin showed a protective relationship with mortality on crude analysis. Vari-
ables that continued to show mortality-associated statistical significance, upon multivariate
analysis, were the presence of dehydration and tachycardia, the existence of a treated infection
before the onset FNEs, along with unremitted fever or neutropenia at days 7 and 14, respec-
tively (Table 6).
After removing non-cancer patients, results did not deviate from the ones recorded in the
whole sample, except for tachycardia, that lost statistical significance upon multivariate analy-
sis (S1 Table).
Discussion
According to study purposes, we herein report on the epidemiological, clinical, and microbio-
logical features of patients with FNEs, their therapeutic management, and disease outcome. To
our knowledge it constitutes the first report in terms of its multicentric and prospective nature
in the region, enrolling a substantial number of FNEs.
Many published studies were based on retrospective data from patients enrolled in cancer
clinical trials [4, 6, 9, 10, 18]. Some prospective studies in adults include only a few centers,
with a smaller number of patients [19–23]. Other researchers, exclusively concentrate on post-
chemotherapy neutropenia [13, 24, 25], only evaluate the first episode of febrile neutropenia
[17], the ones occurring in the context of a new indication of chemotherapy [26], or they do
not report further episodes occurring in the same patient [11].
Our approach of including all FNEs of any etiology, in 346 relatively young patients is closer
to the real clinical scenario. In line with other studies [1, 8, 11, 19, 21, 27], most episodes (77%)
were secondary to chemotherapy, although 106 cases of neutropenia of different etiologies
were recorded. Also, more than half of patients were already hospitalized at the onset of FNEs,
a situation known to confer a higher risk of complications and poor prognosis [11, 17, 25, 28],
as did in the present series, although differences became insignificant upon multivariate analy-
sis. Nearly 20% of cases were already receiving anti-infectious treatment at the onset of FNE,
with this variable behaving as an independent mortality predictor.
According to the MASCC risk index [11], nearly all FNEs (95.3%) fell within the high-risk
category, which is greater than values found in the studies from by Jin et al. (23.6%) [20] or
Rabagliati et al. (41%) [22]. Reduced neutrophil counts at day 0, was found to be compatible
with a poor prognosis of patients [5]. In the present series, a neutrophil count lower than 50
cells/mm3 was also related to a bad prognosis on crude analysis, although differences became
statistical insignificant upon multivariate analysis.
While in only 20% of episodes fever had an unknown origin, in the remaining ones, an
infectious process was detected based on clinical (46%), microbiological (11%) or combined
(23%) criteria. Such amount of recognized infections is higher than findings from other series,
although more recent studies show values above figures recorded in earlier studies [8, 21, 27,
Table 5. MASCC risk index at the onset of FNEs associated mortality.





47 (23.62%) 23 (12.64%) 6 (5.45%) 1 (4.17%) <0.001 0,205
MASCC: Multinational Association for Supportive Care in Cancer.
� Fisher´s exact test
https://doi.org/10.1371/journal.pone.0224299.t005
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29]. The increased presence of infections may be due to the availability of better diagnostic
methods, although it cannot be ruled out that single clinical criteria may have led to an overes-
timation of it. Overall, the distribution of affected sites agrees with findings from other studies
of FNEs, that is pneumonia, the involvement of the gastrointestinal tract, skin and soft tissues,
and the oral cavity [1, 5, 8, 21]. As well as in other reports, bacteremia was present between 10
and 37% of blood samples [5, 8, 24], 15% of present FNEs had positive blood cultures. In a
study carried out in Buenos Aires [19], 36.9% of blood cultures yielded positive results, like
two Chilean studies reporting 30.5% and 31.4% positivity [21, 22]. Our lower bacteremia may
be due to that more than 30% of these patients were under antimicrobial treatment before the
onset of FNEs, either for prophylactic reasons or the existence of a prior infection. We only
found an insignificant trend for Gram-positive bacteriemia in cases under antibiotic prophy-
laxis, probably due to its limited use in our patient series.
Table 6. Variables associated with mortality during febrile neutropenia episodes.
Variable Univariate analysis Binary logistic regression analysis (n = 400)
p Odds Ratio (CI 95%) p Adjusted Odds Ratio (CI 95%)
Sex (women/men) � (n = 515) 0.048 0.60 (0.36–0.99) 0.676 0.86 (0.43–1.73)
Age over 60 years (n = 515) 0.493 1.21 (0.70–2.07)
Chronic obstructive pulmonary disease (n = 515) 0,758 0,56 (0.13–2.43)
Post chemotherapy, solid tumor� (n = 515) 0.008 0.35 (0.16–0.79) 0.764 0.85 (0.30–2,41)
Post chemotherapy, oncohematological malignancies (n = 515) 0.710 1.10 (0.67–1.79)
Hospitalized at the onset of FNE� (n = 512) 0.002 2.25 (1.34–3.80) 0.562 1.27 (0.57–2.83)
Previous radiotherapy (n = 514) 0.390 0.63 (0.22–1.82)
Central venous catheter at the onset of FNE� (n = 514) 0.001 2.40 (1.40–4.11) 0.200 1.73 (0.75–4.01)
Bone marrow transplantation (n = 511) 1.000 0.70 (0.16–3.09)
Previous episodes of febrile neutropenia (n = 515) 0.424 1.23 (0.74–2.4)
Prior Use of Prophylactic antimicrobials (n = 513) 0.864 0.94 (0.44–1.99)
Prior infections�� (n = 514) <0.001 2.58 (1.51–4.42) 0.006 2.91 (1.36–6.22)
Previous fungal invasive infection (n = 515) 0.270 1.68 (0.65–4.30)
Hypotension at the onset of FNE� (n = 511) 0.007 2.17 (1.23–3.82) 0.147 1.87 (0.80–4.33)
Tachycardia at the onset of FNE�� (n = 513) <0.001 2.79 (1.70–4.57) 0.048 2.21 (1.01–4.86)
Oliguria at the onset of FNE (n = 512) 0.168 1.97 (0.81–4,81)
Tachypnea at the onset of FNE� (n = 512) <0.001 2.74 (1.67–4.50) 0.503 1.30 (0.60–2.81)
Dehydration at the onset of FNE�� (n = 512) 0.002 2.58 (1.40–4.75) 0.002 4.02 (1.64–9.87)
Confirmed infection (n = 515) 0.608 1.15 (0.67–1.96)
Use of vancomycin at the onset of FNE� (n = 515) 0.002 2.16 (1.32–3.53) 0.292 1.48 (0.71–3.09)
Unremitted fever at day 7�� (n = 501) <0.001 2.94 (1.77–4.88) 0.046 2.07(1.01–4.24)
Unremitted neutropenia at day 14�� (n = 501) <0.001 3.50 (1.86–6.56) 0.008 3.28 (1.36–7.87)
Initial positive blood culture� (n = 515) 0.003 2.38 (1.32–4.30) 0.150 1.80 (0.81–4.00)
Neutrophils <50 cells/mm3� (n = 464) 0.023 1.82 (1.08–3.08) 0.720 1.13 (0.57–2.25)
ECOG score� 3 at the onset of FNE� (n = 472) <0.001 2.57 (1.53–4.33) 0.289 1.47 (0.72–2.99)
Initial empiric therapy with ceftazidime-amikacin� (n = 507) 0.001 0.36 (0.19–0.68) 0.239 0.61 (0.27–1.39)
G-CSF non administration (n = 515) 0.436 1.22 (0.74–2.02)
MASCC risk Index� 15 at the onset of FNE� (n = 515) <0.001 4.08 (1.83–9.12) 1.000 1.00 (0.31–3.20)
CI: confidence interval (95%); ECOG: Eastern Cooperative Oncology Group; FNE: febrile neutropenia episode; MASCC: Multinational Association for Supportive Care
in Cancer. Variables yielding significant differences in crude analysis were entered into a binary logistic regression model for the multivariate approach.
�Statistical significance only on crude analysis
�� Statistical significance upon employing multivariate analysis
https://doi.org/10.1371/journal.pone.0224299.t006
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Following the Gram-negative to Gram-positive shift in pathogen predominance seen
worldwide during the 1980s, Gram-positive bacteria became predominant in most industrial-
ized regions, with less developed countries still showing a Gram-negative bacteria predomi-
nance, possibly related to lower antibiotic prophylaxis [30–35]. However, in the last decade,
most centers report similar Gram-positive and Gram-negative bacteremia rates in patients
with FNEs [6, 36]. In agreement with studies from the region [21] or Southeast Asia [20], our
series also revealed a slight predominance of Gram-negative bacteria (52.8%). As seen in for-
mer reports [1, 5, 20–22, 27, 37, 38] we also found a predominance of E. coli, K. pneumoniae
and pseudomonas species. Within Gram-positive bacteria, methicillin-susceptible Staphylococ-
cus aureus and methicillin-resistant Staphylococcus aureus followed by coagulase-negative
staphylococci were the prevailing forms. The latter one was also found to predominate among
Gram-positive cocci [20–22, 37].
The fact that G-CSF was indicated in 66% of the FNEs suggests some overuse, as current
guidelines mostly recommend its administration before the establishment of FNEs in patients
at high risk [8, 36, 39–41]. However, recent guideline recommendations indicate that G-CSF
should be considered in patients with fever and neutropenia who are at high risk for infection-
associated complications or have prognostic factors predictive of poor clinical outcomes [40].
The commonest antibiotic schedule employed in this patient series consisted of ceftazidime
plus amikacin, followed by piperacillin/tazobactam, or carbapenems and cefepime as mono-
therapy. The latest guidelines from the Argentine Society of Infectious Diseases [5] and the
Infectious Diseases Society of America [8] and meta-analytical approaches [42] regard ceftazi-
dime plus amikacin as a second choice in favor of the abovementioned alternatives. Most cases
from the present studies were included before the availability of these guidelines [5, 8] when
ceftazidime plus amikacin were recommended as the initial empirical treatment [3, 43, 44].
Nevertheless, since evidence is not conclusive in this regard [45], these therapeutic schedules
continue to be adequate for the management of FNEs, with other recent guidelines still includ-
ing ceftazidime as first-line therapy [36, 46, 47]. In our hands, although initial treatment with
ceftazidime plus amikacin was associated with lower mortality -probably because such treat-
ment was not of first choice for severe patients-, further multivariate analysis revealed no dif-
ferences in mortality depending on the initial antimicrobial therapy.
The fact that vancomycin was indicated in more than half of FNEs raises the possibility of
some overuse. Vancomycin has precise indications in this kind of patients [5, 8], for which
institutional surveillance is currently being implemented to establish more accurate handling
of it. In the same sense, the use of antifungal therapy (35.1% of episodes) seems high, given the
lower amount of cases with confirmed invasive mycosis. The fact that antifungal therapy does
not require mycological confirmation [5, 8, 48, 49], and patients presented prolonged and
severe neutropenia mostly linked to oncohematological malignancies, may have accounted for
such indication.
In line with other studies [3, 41], the mean recovery time of neutrophils situated between 6
and 8 days. Results also revealed that the longer the time for neutrophil recovering (over 14
days in our series) the poorer the prognosis, as seen in former reports [37, 43].
On admission, patients fit well with the high-risk category (95.3%), showing a mortality
rate (14.9%) like the one recorded in a study of comparable risk [22]. Mortality rate increase
with the MASCC prognostic index, in agreement with other studies showing mortality as low
as 3% if the MASCC score was>21, further reaching to 36% provided the MASCC score was
<15 [10]. As stated, patients were at high risk of complications, i.e., increased MASCC risk
index and ECOG scores, low neutrophil counts, prolonged FNEs, many already hospitalized
patients with previous FNEs, Gram-negative bacteremia, as well as a high occurrence of hema-
tological neoplasms, and lung involvement. According to multivariate analysis, mortality-
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associated variables were: unremitted fever at day 7, unremitted neutropenia at day 14, tachy-
cardia, dehydration, and previous infections. The lost of MASCC statistical significance follow-
ing multivariate analysis may be related to the fact that some of the adjusting variables were
also employed for the score construction. As stated, analysis among oncologic patients (the
MASCC score was originally developed for them), revealed a quite similar pattern of mortality
association. Except for tachycardia which was only associated with mortality in the multivari-
ate analysis from the whole patient sample. The lower number of FNEs among oncologic
patients may account for such lost of statistical association.
The study by Gómez Roca et al. [19] identified the presence of comorbidities, tachypnea,
systolic hypotension, and a clinical infectious process as factors of poor prognosis.
This type of observational study has limitations. For instance, there existed variations in
causes of febrile neutropenia, and features of centers in charge of patients. Management was
decided at each center according to its usual practice, likely contributing to some therapeutic
dissimilarities. In the same sense, surveillance for multidrug-resistant bacteria was not usually
carried out in many centers, for which data regarding this issue is lacking, as did information
about Clostridium difficile toxin. Also, there was no information on lifestyle parameters, pri-
mary healthcare data, or socioeconomic data, emerging as potential confounding factors.
Against such constraints, our study did collect data about underlying diseases which may
influence study endpoints and revealed a consistent and relatively high association, likely to
reduce the risk of unknown confounders. These facts, along with the proper representativeness
of centers allowing to get an informative number of cases strengthen study validity serving to
expand present knowledge on the clinical and microbiological features of patients with febrile
neutropenia in Argentina. Present kind of observational data also help to identify associations
between exposures and outcomes, and the strength of such associations, providing useful
information for clinical decisions and better management of FNEs in the region.
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